Skip to content

J. V. Vande Voort

2 papers in the library · publishing 2017-2022

Papers

Sort Most recent Most cited

Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression.

Journal of Affective Disorders December 1, 2022 Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera et al.

BACKGROUND Intravenous (IV) ketamine is an effective therapy for treatment-resistant depression. A large data base is confirmatory and steadily expanding. Qualitative studies can inform best practices and suggest new research directions. As part of a clinical trial designed to identify biomarkers of ketamine response, a qualitative study was conducted to characterize experiences with: receiving...

Corrigendum to "Continuation phase intravenous ketamine in adults with treatment-resistant depression" [J. Affect. Disord. 206 (2016) 300-304].

Journal of Affective Disorders September 27, 2017 J. V. Vande Voort, Robert J Morgan, Simon Kung et al. correction

We recently became aware of an error in the classification of one study subject's positive treatment response status at the end of the post-continuation phase of this study. We originally reported that all 5 subjects who achieved depressive symptom remission during the acute phase of the study (and thus received 4 weekly continuation phase ketamine infusions) were classified as responders at...